异喹胍氧化多态性与肺癌之间不存在相关性。
Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer.
作者信息
Duche J C, Joanne C, Barre J, de Cremoux H, Dalphin J C, Depierre A, Brochard P, Tillement J P, Bechtel P
机构信息
Laboratoire hospitalo-universitaire de Pharmacologie, Creteil, France.
出版信息
Br J Clin Pharmacol. 1991 May;31(5):533-6. doi: 10.1111/j.1365-2125.1991.tb05575.x.
Abstract
- Determination of debrisoquine oxidation phenotype was carried out in 119 healthy subjects, 135 patients with chronic bronchitis and 153 patients with lung cancer, all of Caucasian origin. 2. A non-Gaussian distribution of the log D/HD ratio was observed in the three groups. 3. Assuming an antimode of 1.12, the proportion of PMs was found to be 6.7% in healthy subjects, 8.9% in chronic bronchitics and 6.5% in patients with lung cancer. These differences were not significant. 4. The presence of a lung tumour itself had no influence on phenotype in a group of 14 patients who were phenotyped before and after surgery. 5. We conclude that a link between debrisoquine phenotype and lung cancer is unlikely.
摘要
- 对119名健康受试者、135名慢性支气管炎患者和153名肺癌患者进行了异喹胍氧化表型测定，所有受试者均为白种人。2. 在三组中均观察到log D/HD比值呈非高斯分布。3. 假设反众数为1.12，发现健康受试者中慢代谢者的比例为6.7%，慢性支气管炎患者中为8.9%，肺癌患者中为6.5%。这些差异不显著。4. 在一组14名手术前后进行表型测定的患者中，肺部肿瘤本身的存在对表型没有影响。5. 我们得出结论，异喹胍表型与肺癌之间不太可能存在联系。
相似文献
1
Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer.异喹胍氧化多态性与肺癌之间不存在相关性。
Br J Clin Pharmacol. 1991 May;31(5):533-6. doi: 10.1111/j.1365-2125.1991.tb05575.x.
2
Is there a link between debrisoquine oxidation phenotype and lung cancer susceptibility?
Biomed Pharmacother. 1991;45(8):359-62. doi: 10.1016/0753-3322(91)90066-3.
3
Evidence for the polymorphic oxidation of debrisoquine in the Thai population.泰国人群中异喹胍多态性氧化的证据。
Br J Clin Pharmacol. 1990 Feb;29(2):244-7. doi: 10.1111/j.1365-2125.1990.tb03627.x.
4
Debrisoquine oxidation phenotype and susceptibility to lung cancer.异喹胍氧化表型与肺癌易感性
Br J Clin Pharmacol. 1990 Jan;29(1):101-9. doi: 10.1111/j.1365-2125.1990.tb03608.x.
5
Debrisoquine metabolism and lung cancer risk.
Cancer Epidemiol Biomarkers Prev. 1995 Jan-Feb;4(1):41-8.
6
Polymorphic oxidation of debrisoquine in lung cancer patients.
Eur J Cancer. 1991;27(2):158-61. doi: 10.1016/0277-5379(91)90477-u.
7
Lung cancer and the debrisoquine metabolic phenotype.
J Natl Cancer Inst. 1990 Aug 1;82(15):1264-72. doi: 10.1093/jnci/82.15.1264.
8
Debrisoquine oxidation phenotype during neuroleptic monotherapy.抗精神病药物单一疗法期间的异喹胍氧化表型
Eur J Clin Pharmacol. 1991;41(5):467-70. doi: 10.1007/BF00626371.
9
Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.美托洛尔代谢与异喹胍氧化多态性——群体与家系研究
Br J Clin Pharmacol. 1985 Dec;20(6):555-66. doi: 10.1111/j.1365-2125.1985.tb05112.x.
10
Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.
Klin Wochenschr. 1988;66 Suppl 11:87-97.
引用本文的文献
1
Interaction between dose and susceptibility to environmental cancer: a short review.剂量与环境致癌易感性之间的相互作用：简要综述
Environ Health Perspect. 1997 Jun;105 Suppl 4(Suppl 4):749-54. doi: 10.1289/ehp.97105s4749.
2
The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.
Eur J Clin Pharmacol. 1997;51(5):389-93. doi: 10.1007/s002280050219.
3
The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype.异喹胍代谢表型与基于DNA的检测：肺癌与异喹胍代谢表型关联中错误分类的影响
Environ Health Perspect. 1992 Nov;98:101-5. doi: 10.1289/ehp.9298101.
4
Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients.肺癌患者中细胞色素P-450IID6、谷胱甘肽S-转移酶Mu类和芳胺N-乙酰转移酶的突变基因。
Clin Investig. 1992 Mar-Apr;70(3-4):307-19. doi: 10.1007/BF00184667.
本文引用的文献
1
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.对英国白人人群中异喹胍氧化遗传多态性的家系及群体研究。
J Med Genet. 1980 Apr;17(2):102-5. doi: 10.1136/jmg.17.2.102.
2
Alpha-helical coiled-coil structures of Trypanosoma brucei variable surface glycoproteins.
Nature. 1984;311(5982):169-71. doi: 10.1038/311169a0.
3
Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.奎尼丁：体内对司巴丁和异喹胍氧化有强效抑制作用。
Br J Clin Pharmacol. 1986 Aug;22(2):199-200. doi: 10.1111/j.1365-2125.1986.tb05251.x.
4
The influence of enzyme induction on polymorphic sparteine oxidation.酶诱导对多态性司巴丁氧化的影响。
Br J Clin Pharmacol. 1986 Jul;22(1):49-53. doi: 10.1111/j.1365-2125.1986.tb02879.x.
5
Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.奎尼丁以及对那些被归类为异喹胍代谢缓慢者体内消除受损药物的鉴定。
Br J Clin Pharmacol. 1986 Dec;22(6):739-43. doi: 10.1111/j.1365-2125.1986.tb02969.x.
6
7
Polymorphism of dextromethorphan oxidation in a French population.法国人群中右美沙芬氧化的多态性。
Br J Clin Pharmacol. 1987 Nov;24(5):676-9. doi: 10.1111/j.1365-2125.1987.tb03230.x.
8
P450 genes: structure, evolution, and regulation.细胞色素P450基因：结构、进化与调控
Annu Rev Biochem. 1987;56:945-93. doi: 10.1146/annurev.bi.56.070187.004501.
9
Phenotyping polymorphic drug metabolism in the French Caucasian population.对法国白种人群中多态性药物代谢进行表型分析。
Eur J Clin Pharmacol. 1988;35(2):167-71. doi: 10.1007/BF00609247.
10
Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.异喹胍代谢缺陷人类常见遗传缺陷的特征分析。
Nature. 1988 Feb 4;331(6155):442-6. doi: 10.1038/331442a0.
Zotero 插件